Back to all papers

Artificial Intelligence in Pulmonary Hypertension: Current State and Future Prospects.

August 21, 2026pubmed logopapers

Authors

Li Z,Xu X,Li J,Fang Y,He Y,Tang J,Yang Z,Xie H,Yuan H

Affiliations (3)

  • Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China.
  • Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510080 Guangzhou, Guangdong, China.
  • Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China.

Abstract

Pulmonary hypertension (PH) remains diagnostically challenging due to the associated non-specific symptomatology and frequent diagnostic delays, both of which contribute to increased morbidity and mortality. Meanwhile, right heart catheterization is the diagnostic gold standard; nonetheless, the invasive nature and limited accessibility of this technique limit its routine use, particularly in resource-constrained settings. This review evaluates computational approaches that may enhance PH diagnosis through advanced analysis of cardiovascular imaging data. We conducted a comprehensive literature review focusing on computer-assisted diagnostic methods in PH across multiple imaging modalities, including electrocardiogram, chest X-ray, echocardiography, cardiac magnetic resonance (CMR) imaging, and cardiac computed tomography (CCT). Eligible studies were analyzed for diagnostic performance, clinical applicability, and methodological rigor. Preliminary studies have demonstrated promising performance in detecting early or subclinical PH phenotypes across various imaging platforms. Advanced imaging modalities benefit from automated segmentation and quantitative analysis, and CMR- and CT-based approaches demonstrate high diagnostic accuracy. Current artificial intelligence (AI) models face significant challenges related to clinical interpretability, external validation across diverse populations, and seamless integration into existing diagnostic workflows. Most studies are based on single-center retrospective cohorts, underscoring the need for multicenter prospective validation. To address these challenges, future research must prioritize advancing methodological transparency through explainable AI (XAI) and ensuring data privacy via federated learning. Crucially, the next phase of innovation lies in synergistic multimodal fusion (MMF) architectures that synthesize heterogeneous data-ranging from imaging to hemodynamics-to enhance phenotypic precision. Furthermore, leveraging large language models (LLMs) for computational phenotyping from electronic health records offers a scalable solution for identifying undiagnosed patients. Finally, realizing clinical translation requires rigorous multicenter prospective validation and seamless integration into existing workflows to ensure these tools effectively support decision-making in real-world practice. While computational approaches in PH diagnostics show promise for improving early detection and diagnostic accuracy, significant challenges remain before widespread clinical adoption. Future development should prioritize multicenter validation, standardized frameworks integrating multi-parametric imaging with clinical biomarkers, and transparent methodologies to support clinical decision-making. The integration of these computational tools into conventional diagnostic pathways may enhance PH management through earlier detection and more precise risk stratification.

Topics

Journal ArticleReview

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.